Emily M. Gesner

1.1k total citations
14 papers, 811 citations indexed

About

Emily M. Gesner is a scholar working on Molecular Biology, Hematology and Infectious Diseases. According to data from OpenAlex, Emily M. Gesner has authored 14 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 7 papers in Hematology and 1 paper in Infectious Diseases. Recurrent topics in Emily M. Gesner's work include Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Emily M. Gesner is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Emily M. Gesner collaborates with scholars based in Canada, United States and Germany. Emily M. Gesner's co-authors include Andrew M. MacMillan, Matthew J. Schellenberg, Henrik C. Hansen, Kevin G. McLure, Ulrich Keller, Jonas A. Nilsson, Lisa M. Nilsson, Zhoulei Li, Olesya A. Kharenko and Joydeep Bhadury and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and PLoS ONE.

In The Last Decade

Emily M. Gesner

14 papers receiving 791 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily M. Gesner Canada	10	751	182	90	65	54	14	811
Eric Kowarz Germany	11	429 0.6×	126 0.7×	59 0.7×	81 1.2×	71 1.3×	24	621
Diane Giannola United States	11	345 0.5×	198 1.1×	76 0.8×	82 1.3×	121 2.2×	18	665
Sergey O. Sulima Belgium	11	633 0.8×	25 0.1×	57 0.6×	108 1.7×	63 1.2×	12	696
Maiken Søndergaard Kristiansen United Kingdom	6	1.0k 1.4×	42 0.2×	132 1.5×	72 1.1×	53 1.0×	6	1.1k
David C. Dorn Germany	9	378 0.5×	122 0.7×	114 1.3×	147 2.3×	46 0.9×	14	597
Victoria V. Hargreaves United States	7	420 0.6×	62 0.3×	48 0.5×	33 0.5×	118 2.2×	9	571
Shaina N. Porter United States	14	597 0.8×	108 0.6×	71 0.8×	93 1.4×	124 2.3×	21	758
Man-Gen Song China	9	404 0.5×	26 0.1×	66 0.7×	71 1.1×	46 0.9×	12	540
Nicolas Paquet Australia	12	404 0.5×	32 0.2×	51 0.6×	69 1.1×	53 1.0×	24	496
Shweta Tyagi India	13	514 0.7×	42 0.2×	34 0.4×	78 1.2×	77 1.4×	26	768

Countries citing papers authored by Emily M. Gesner

Since Specialization

Citations

This map shows the geographic impact of Emily M. Gesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily M. Gesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily M. Gesner more than expected).

Fields of papers citing papers by Emily M. Gesner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily M. Gesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily M. Gesner. The network helps show where Emily M. Gesner may publish in the future.

Co-authorship network of co-authors of Emily M. Gesner

This figure shows the co-authorship network connecting the top 25 collaborators of Emily M. Gesner. A scholar is included among the top collaborators of Emily M. Gesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily M. Gesner. Emily M. Gesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Gesner, Emily M., Sarah Attwell, Olesya A. Kharenko, et al.. (2021). Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2. ACS Omega. 6(33). 21327–21338. 9 indexed citations

Kharenko, Olesya A., Emily M. Gesner, Reena G. Patel, et al.. (2016). RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochemical and Biophysical Research Communications. 477(1). 62–67. 46 indexed citations

Attwell, Sarah, Ravi Jahagirdar, Karen Norek, et al.. (2016). Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 76(14_Supplement). LB–207. 7 indexed citations

Duffy, Bryan C., Shuang Liu, Greg S. Martin, et al.. (2015). Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design. Bioorganic & Medicinal Chemistry Letters. 25(14). 2818–2823. 21 indexed citations

Attwell, Sarah, Eric Campeau, Ravi Jahagirdar, et al.. (2015). Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies. Molecular Cancer Therapeutics. 14(12_Supplement_2). C86–C86. 8 indexed citations

Bhadury, Joydeep, Lisa M. Nilsson, Zhoulei Li, et al.. (2014). Abstract 5495: BET bromodomain inhibitors abrogate cell cycle progression and induces apoptosis in Myc-induced mouse lymphoma cells without affecting MYC transcription. Cancer Research. 74(19_Supplement). 5495–5495. 1 indexed citations

Bhadury, Joydeep, Lisa M. Nilsson, Somsundar Veppil Muralidharan, et al.. (2014). BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences. 111(26). E2721–30. 182 indexed citations

McLure, Kevin G., Emily M. Gesner, Laura Tsujikawa, et al.. (2013). RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist. PLoS ONE. 8(12). e83190–e83190. 147 indexed citations

Campeau, Eric, Ravi Jahagirdar, Emily M. Gesner, et al.. (2013). Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells.. Cancer Research. 73(8_Supplement). LB–92. 1 indexed citations

10.

Schellenberg, Matthew J., Emily M. Gesner, J.B. Bonanno, et al.. (2012). Cas5d processes pre-crRNA and is a member of a larger family of CRISPR RNA endonucleases. RNA. 18(11). 2020–2028. 73 indexed citations

11.

Chaulk, Steven G., Oliver A. Kent, Zhizhong Xu, et al.. (2011). Role of pri-miRNA tertiary structure in miR-17~92 miRNA biogenesis. RNA Biology. 8(6). 1105–1114. 82 indexed citations

12.

Gesner, Emily M., et al.. (2011). Recognition and maturation of effector RNAs in a CRISPR interference pathway. Nature Structural & Molecular Biology. 18(6). 688–692. 126 indexed citations

13.

Ritchie, Dustin B., Matthew J. Schellenberg, Emily M. Gesner, et al.. (2008). Structural elucidation of a PRP8 core domain from the heart of the spliceosome. Nature Structural & Molecular Biology. 15(11). 1199–1205. 52 indexed citations

14.

Wu, Tao, Chao Liang, Matthew J. Schellenberg, et al.. (2006). FRET Analysis of in Vivo Dimerization by RNA-editing Enzymes. Journal of Biological Chemistry. 281(24). 16530–16535. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact